An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

Condition:   Lyme Disease Interventions:   Biological: VLA15;   Other: Saline Sponsors:   Pfizer;   Valneva Austria GmbH Not yet recruiting

Source: ClinicalTrials.gov - July 28, 2022 Category: Research Source Type: clinical trials